Top

Journal of Clinical Immunology

Published in:

01-05-2021 | Fibrinolytic Therapy | Letter to Editor

C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19

Authors: T. M. Ayodele Adesanya, Courtney M. Campbell, Lijun Cheng, Princess U. Ogbogu, Rami Kahwash

Published in: Journal of Clinical Immunology | Issue 4/2021

Excerpt

To the Editor: …

Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. 2020;141:1739–41. https://doi.org/10.1161/CIRCULATIONAHA.120.047419.CrossRefPubMed

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20:343–4. https://doi.org/10.1038/s41577-020-0320-7.CrossRefPubMed

Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74. https://doi.org/10.1038/s41577-020-0311-8.CrossRefPubMed

Jiang H, Wagner E, Zhang H, Frank MM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med. 2001;194(11):1609–16. https://doi.org/10.1084/jem.194.11.1609.CrossRefPubMedPubMedCentral

Panagiotou A, Trendelenburg M, Osthoff M. The lectin pathway of complement in myocardial ischemia/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor. Front Immunol. 2018;9:1151. https://doi.org/10.3389/fimmu.2018.01151.CrossRefPubMedPubMedCentral

Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382(12):1136–48. https://doi.org/10.1056/NEJMra1808012.CrossRefPubMed

Cotiguala L, Coover K, Bewtra A, Malesker M. Advances in the pharmacotherapy of hereditary angioedema. US Pharmacist. 2015;40(10):HS17–21.

Batarseh E, Kersten BP, Pinelo AC, Nadler JN, Schwartz SA. Angioedema in African Americans patients hospitalized for COVID-19. Am J Respir Crit Care Med. 2020;202:1581–4. https://doi.org/10.1164/rccm.202006-2223LE.CrossRefPubMedPubMedCentral

Roche J, Roche R. An open letter to the scientific community on the possible role of dysregulated bradykinin signaling in COVID-19 respiratory complications. 2020.

10.

Tolouian R, Vahed S, Ghiyasvand S, Tolouian A, Ardalan M. COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. J Renal Inj Prev. 2020;9(2):e19.CrossRef

11.

van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JWM, de Mast Q, Brüggemann RJ, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife. 2020;9:e57555. https://doi.org/10.7554/eLife.57555.CrossRefPubMedPubMedCentral

12.

Urwyler P, Moser S, Charitos P, Heijnen I, Rudin M, Sommer G, et al. Treatment of COVID-19 with Conestat Alfa, a regulator of the complement, contact activation and kallikrein-kinin system. Front Immunol. 2020;11:2072. https://doi.org/10.3389/fimmu.2020.02072.CrossRefPubMedPubMedCentral

13.

van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, van der Hoeven HG, Maas C, Netea MG, et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open. 2020;3(8):e2017708. https://doi.org/10.1001/jamanetworkopen.2020.17708.CrossRefPubMedPubMedCentral

14.

I-SPY COVID-19 TRIAL: an adaptive platform trial for critically Ill patients. https://clinicaltrials.gov/show/NCT04488081.

15.

Lanadelumab for treatment of COVID-19 disease. https://clinicaltrials.gov/show/NCT04422509.

16.

Prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19. https://clinicaltrials.gov/show/NCT04530136.

17.

Campbell CM. The opening salvo of anti-complement therapy against COVID-19. Lancet Rheumatol. 2020;2:e729–30. https://doi.org/10.1016/S2665-9913(20)30353-2.CrossRefPubMedPubMedCentral

18.

Pfefferle S, Schopf J, Kogl M, Friedel CC, Muller MA, Carbajo-Lozoya J, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011;7(10):e1002331. https://doi.org/10.1371/journal.ppat.1002331.CrossRefPubMedPubMedCentral

19.

Srinivasan S, Cui H, Gao Z, Liu M, Lu S, Mkandawire W, et al. Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins. Viruses. 2020;12:4. https://doi.org/10.3390/v12040360.CrossRef

20.

McDowall MD, Scott MS, Barton GJ. PIPs: human protein-protein interaction prediction database. Nucleic Acids Res. 2009;37(Database issue):D651–6. https://doi.org/10.1093/nar/gkn870.CrossRefPubMed

21.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80 e8. https://doi.org/10.1016/j.cell.2020.02.052.CrossRefPubMedPubMedCentral

22.

Carnivali G. Analyzing characteristics of the genetic network generated by genes linked to COVID-19. InterAm J Med Health. 2020;3.

23.

Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182:59–72.e15. https://doi.org/10.1016/j.cell.2020.05.032.CrossRefPubMedPubMedCentral

24.

Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, Kim J, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020;26(10):1609–15. https://doi.org/10.1038/s41591-020-1021-2.CrossRefPubMedPubMedCentral

25.

Caccia S, Suffritti C, Carzaniga T, Berardelli R, Berra S, Martorana V, et al. Intermittent C1-inhibitor deficiency associated with recessive inheritance: functional and structural insight. Sci Rep. 2018;8(1):977. https://doi.org/10.1038/s41598-017-16667-w.CrossRefPubMedPubMedCentral

26.

Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52(1):91–112.PubMed

27.

Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015;235(2):185–95. https://doi.org/10.1002/path.4454.CrossRefPubMed

28.

Guzzi PH, Mercatelli D, Ceraolo C, Giorgi FM. Master regulator analysis of the SARS-CoV-2/human interactome. J Clin Med. 2020;9:4. https://doi.org/10.3390/jcm9040982.CrossRef

29.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26:842–4. https://doi.org/10.1038/s41591-020-0901-9.CrossRefPubMed

30.

Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761–70. https://doi.org/10.1080/22221751.2020.1747363.CrossRefPubMedPubMedCentral

31.

Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27:883–890.e2. https://doi.org/10.1016/j.chom.2020.04.017.CrossRefPubMedPubMedCentral

32.

Yan Q, Li P, Ye X, Huang X, Mo X, Wang Q et al. Longitudinal peripheral blood transcriptional analysis of COVID-19 patients captures disease progression and reveals potential biomarkers. medRxiv. 2020:2020.05.05.20091355. doi:https://doi.org/10.1101/2020.05.05.20091355.

33.

Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108–21. https://doi.org/10.1001/jama.2018.16773.CrossRefPubMedPubMedCentral

34.

Crowther M, Bauer KA, Kaplan AP. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc. 2014;35(6):444–53. https://doi.org/10.2500/aap.2014.35.3799.CrossRefPubMed

35.

Ozen A, Comrie WA, Ardy RC, Dominguez Conde C, Dalgic B, Beser OF, et al. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis. N Engl J Med. 2017;377(1):52–61. https://doi.org/10.1056/NEJMoa1615887.CrossRefPubMedPubMedCentral

Title: C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19
Authors: T. M. Ayodele Adesanya
Courtney M. Campbell
Lijun Cheng
Princess U. Ogbogu
Rami Kahwash
Publication date: 01-05-2021
Publisher: Springer US
Keywords: Fibrinolytic Therapy
Severe Acute Respiratory Syndrome Coronavirus
COVID-19
Hereditary Angioedema
Hereditary Angioedema
Published in: Journal of Clinical Immunology / Issue 4/2021
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-021-00972-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2021

Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation

Expanding the Nude SCID/CID Phenotype Associated with FOXN1 Homozygous, Compound Heterozygous, or Heterozygous Mutations

Correction to: Helicobacter cinaedi-Associated Refractory Cellulitis in Patients with X-Linked Agammaglobulinemia

Clinical and Immunological Heterogeneity in Japanese Patients with Gain-of-Function Variants in STAT3

Toxoplasmosis-Associated Hemophagocytic Lymphohistiocytosis in Allogeneic Transplantation

The First Case of BENTA Disease (B Cell Expansion with NF-κB and T Cell Anergy) from Iran

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage